Abstract 2442: Baseline single-cell mass distributions correlate with clinical response to acalabrutinib, venetoclax, and obinutuzumab in mantle cell lymphoma
Research investigates how baseline cell mass predicts therapy response in mantle cell lymphoma, indicating potential biomarkers for treatment efficacy.
Key Points
To examine if baseline single-cell mass distributions can predict clinical responses to BTKi-based therapies in mantle cell lymphoma.
Analyzed tumor cells from treatment-naïve MCL patients via fluorescence-activated cell sorting.
Measured single-cell buoyant mass using suspended microchannel resonators.
Determined durable response and non-durable response based on patient outcomes over 12 months.
Performed parallel CyTOF profiling on tumor samples.
Median mass of MCL cells was significantly higher in non-durable responders than durable responders.
The fraction of cells over 15 pg correlated with the Ki-67 index and was linked to BTK inhibitor sensitivity.
Increased tumor cell mass was associated with elevated PD-1 expression on CD4+ T cells and activated Tfh cells.
Findings suggest heightened BCR signaling may influence both tumor proliferation and immune response.